SNS 851
Alternative Names: SNS-851Latest Information Update: 28 Apr 2026
At a glance
- Originator Oneness Biotech
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Metabolic disorders
- Preclinical Weight gain
Most Recent Events
- 30 Mar 2026 Preclinical trials in Weight gain in Taiwan (SC) (Oneness Biotech pipeline, March 2026)
- 30 Mar 2026 Pharmacodynamics data from a preclinical trial in wight gain released by Oneness Biotec
- 01 Mar 2026 Phase-I clinical trials in Metabolic disorders (In volunteers) in Australia (SC) (NCT07417124)